Moore Capital Management’s BridgeBio Oncology BBOT Stock Holding History

Moore Capital Management’s Portfolio BBOT Stock Details BBOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$762K	Hold	100,000	–	–	0.01%	509
2026 Q1	$895K	Hold	100,000	–	–	0.02%	381
2025 Q4	$1.25M	Hold	100,000	–	–	0.02%	434
2025 Q3	$1.16M	Hold	100,000	–	–	0.02%	405
2025 Q2	$1.06M	Hold	100,000	–	–	0.01%	372
2025 Q1	$1.13M	Hold	100,000	–	–	0.02%	306
2024 Q4	$1.05M	Hold	100,000	–	–	0.01%	371
2024 Q3	$1.04M	Hold	100,000	–	–	0.02%	349
2024 Q2	$1.02M	Hold	100,000	–	–	0.02%	316
2024 Q1	$1.03M	Buy	+100,000	New	+$1.04M	0.02%	311

Other funds holding BBOT

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Moore Capital Management's BBOT Position: Q2 2026 in Review

Moore Capital Management held its BridgeBio Oncology (BBOT) position steady in Q2 2026 at 100,000 shares worth $762K. The position accounts for 0.01% of the portfolio, ranked #509.

Moore Capital Management first reported a position in BBOT in Q1 2024 and has held it in 10 quarters since. The position peaked at $1.25M in Q4 2025. 57 funds tracked by Wall St. Rank hold BBOT as of Q2 2026.

Moore Capital Management held 100,000 shares of BridgeBio Oncology worth $762K as of Q2 2026.
Moore Capital Management left its BridgeBio Oncology share count unchanged in Q2 2026.
BridgeBio Oncology made up 0.01% of Moore Capital Management's portfolio in Q2 2026, its #509 holding.
Moore Capital Management first reported a position in BridgeBio Oncology in Q1 2024 and has held it in 10 quarters since.
Moore Capital Management's BridgeBio Oncology position peaked at $1.25M in Q4 2025.
57 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q2 2026.

Based on Moore Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.